Table 2.
Baseline demographic and clinical characteristics of the participants with MMN
| Sequence Ad N = 12 | Sequence Bd N = 10 | |
|---|---|---|
| Male: female ratio, n (%) | 11 (91.7):1 (8.3) | 8 (80.0):2 (20.0) |
| Age (y) | ||
| Median (min, max) | 47.0 (32.0, 78.0) | 49.0 (31.0, 64.0) |
| BMI (kg/m2)a | ||
| Median (min, max) | 26.3 (18.1, 32.8) | 24.7 (22.2, 35.1) |
| European Federation of Neurological Societies/Peripheral Nerve Society diagnostic criteria, n (%) | ||
| Definite | 11 (91.7) | 8 (80.0) |
| Probable | 1 (8.3) | 2 (20.0) |
| Time since first symptoms (y)b | ||
| Median (min, max) | 5.4 (1.0, 18.0) | 8.3 (1.8, 20.5) |
| Time since diagnosis (y)b | ||
| Median (min, max) | 3.4 (0.4, 9.8) | 4.7 (1.2, 20.5) |
| Prior treatment of MMN other than IVIg since diagnosis, n (%) | ||
| Immunosuppressive | 1 (8.3%) | 3 (30.0%) |
| Otherc | 1 (8.3%) | 0 |
| MMRC 10‐sum score | ||
| Median (min, max) | 97.5 (84.0, 100.0) | 96.0 (60.0, 100.0) |
| MMRC new 10‐sum score | ||
| Median (min, max) | 93.0 (63.0, 97.0) | 95.0 (45.0, 99.0) |
| Rasch‐built MMRC 10‐sum score | ||
| Median (min, max) | 58.0 (47.0, 60.0) | 56.5 (34.0, 60.0) |
| MMRC 14‐sum score | ||
| Median (min, max) | 133.0 (98.0, 137.0) | 135.0 (74.0, 139.0) |
| Total INCAT disability score | ||
| Median (min, max) | 2.0 (1.0, 6.0) | 3.5 (0.0, 5.0) |
| Normalised grip strength (%) | ||
| Median (min, max) | 60.0 (0.0, 130.0) | 72.0 (6.0, 115.0) |
Abbreviations: BMI, body mass index; IVIg, intravenous immunoglobulin, MMN, multifocal motor neuropathy.
Modified Medical Research Council (MMRC) 10‐sum score and MMRC new 10‐sum score (range 0‐100), MMRC 14‐sum score (range 0‐140), Rasch‐built MMRC 10‐sum score (range 0‐60), a higher value indicates better muscle strength; Total INCAT disability score (range 0‐10), a higher value indicates maximal disability.
BMI = weight (kg)/height (m)2.
Time derived as: (screening date − event date)/365.25.
Participant was treated with gabapentin, chloraminophene, cetirizine, and prednisolone.
In sequence A, participants were treated first with Kiovig® for 21 to 25 weeks (period 1) then with IqYmune® for 21 to 25 weeks (period 2). In sequence B, participants were treated first with IqYmune® and then with Kiovig®.